Spots Global Cancer Trial Database for A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis

Official Title: A Multicenter, Open-label Clinical Study of the JAK Inhibitor Ruxolitinib (INC424) in Patients With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis

Study ID: NCT02087059

Conditions

Primary Myelofibrosis (MF)

Interventions

Ruxolitinib

Study Description

Brief Summary: This is an open-label, multicenter clinical study in order to collect and examine data concerning the safety and efficacy of ruxolitinib in patients with Primary Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, Post-Essential Thrombocythemia (ET) MF.

Detailed Description:

Keywords

Post-Polycythemia Vera (PV) MF

Post-Essential Thrombocythemia (ET) MF

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Novartis Investigative Site, Nagoya-city, Aichi, Japan

Novartis Investigative Site, Matsuyama, Ehime, Japan

Novartis Investigative Site, Toon-city, Ehime, Japan

Novartis Investigative Site, Fukuoka-city, Fukuoka, Japan

Novartis Investigative Site, Kurume-city, Fukuoka, Japan

Novartis Investigative Site, Maebashi-city, Gunma, Japan

Novartis Investigative Site, Sapporo-city, Hokkaido, Japan

Novartis Investigative Site, Kobe-city, Hyogo, Japan

Novartis Investigative Site, Kumamoto City, Kumamoto, Japan

Novartis Investigative Site, Kyoto-city, Kyoto, Japan

Novartis Investigative Site, Tsu-city, Mie, Japan

Novartis Investigative Site, Sendai-city, Miyagi, Japan

Novartis Investigative Site, Miyazaki-city, Miyazaki, Japan

Novartis Investigative Site, Okayama-city, Okayama, Japan

Novartis Investigative Site, Hirakata-city, Osaka, Japan

Novartis Investigative Site, OsakaSayama, Osaka, Japan

Novartis Investigative Site, Suita-city, Osaka, Japan

Novartis Investigative Site, Shimotsuke-city, Tochigi, Japan

Novartis Investigative Site, Bunkyo-ku, Tokyo, Japan

Novartis Investigative Site, Shinjuku-ku, Tokyo, Japan

Novartis Investigative Site, Chuo-city, Yamanashi, Japan

Novartis Investigative Site, Akita, , Japan

Novartis Investigative Site, Gifu, , Japan

Contact Details

Name: Novartis Pharmaceuticals

Affiliation: Novartis Pharmaceuticals

Role: STUDY_DIRECTOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: